Recycle Loop AAnchor Mg/kg Anthranilamide Mg/kg Virgin

KEY CHARACTERISTICS • Compliant with BPR EU No. 528/2012 PT19 requirements • Designed for incorporation into cable jackets exposed to rats and termites attack • Efficacy at low dosing 2–4% • “Low concern” and long lasting active substance • Compatible with most polymers TARGET MARKET AND APPLICATIONS Appropriate for all applications where cables can be exposed to rats and termites.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Standard concentrates in a PE carrier and on request in PP • Pre-colored formulations can be supplied in specific resins selected for the application REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN DRUG TYPE COLOR DESCRIPTION PANTONE REFERENCE AVIENT PRODUCT CODE PE BASED Adrenergic agonist combinations Light Green 373 C PE6M176349 Adrenergic agonists Purple 2583 C PE4M176057 Anti-infectives Tan 467 C PE8M176130 Anti-inflammatory, nonsteroidal Grey Cool Grey 4 C PE7M176184 steroids Pink 197 C PE3M176237 Anti-inflammatory, immunomodulators Olive Green 5763 C On request Beta-blockers Yellow Yellow C PE1M176160 Beta-blocker combinations Dark Blue 281 C PE5M176272 Carbonic anhydrase inhibitors Orange 1585 C PE2M176089 Cytotoxic Black 6 C PL9M176008 Miotics Dark Green 348 C PE6M176267 Mydriatics and cycloplegics Red 1797 C PE3M176236 Prostaglandin analogues Turquoise 326 C PE5M176273 Healthcare use limitations apply—see below.

Without limiting the generality of this statement, Avient products shall not be used in any medical device application intended for: (1) exposure to human tissue or body fluids for 30 days or greater; (2) “plastic” (cosmetic or reconstructive) surgery use; (3) reproductive implants or any birth control device; or (4) any critical component in a permanently (greater than 30 days) implanted medical device that supports or sustains human life.

FDA approved materials • European regulations and directives 4 • Mercosur (S.A.) region regulations • GB (China) national standards • Avient No Surprises PledgeSM To consult with one of our experts, contact us at +1.844.4AVIENT or submit your request at Connect Now. www.avient.com Take advantage of our breadth of polymer solutions, along with our design capabilities and industry expertise, on your path to bottle optimization.

Omezení distribuce – omezení svobody distributora opětovně prodávat mimo přidělené oblasti nebo určitým zákazníkům či kategoriím zákazníků. 4. Revidované antimonopolní zásady 2021 4 Obsah Zaměstnanci společnosti Avient by si měli být vědomi toho, zda pracují na trhu, kde má společnost Avient monopolní sílu (schopnost jednostranně zvýšit ceny nebo vyřadit konkurenty) nebo podíl na trhu, který naznačuje monopolní sílu (podíl na trhu nad 40 %). Nesnažte se žádným způsobem získat přímo od konkurentů informace (zejména o cenách). 4.

Закон Робинсона-Патмана запрещает следующее: • ценовую дискриминацию, дискриминацию при оказании рекламных услуг и предоставлении скидок конкурирующим покупателям, если удовлетворены определенные юрисдикционные требования и не применяется ни одна из защитных мер Закона; • стимулировать или сознательно допускать установление дискриминационной цены. 4. Поскольку может быть трудно отличить противоправное поведение такого вида от правомерных действий, следует проконсультироваться с юридическим отделом компании Avient перед наложением каких-либо из этих ограничений. 4. Запрещается иным образом получать информацию (в частности, о цене) непосредственно от конкурентов. 4.

Herzien Antitrustbeleid 2021 4 Inhoudsopgave • Territoriale en klantbeperkingen: beperking van de vrijheid van een distributeur om door te verkopen buiten een toegewezen gebied of aan bepaalde klanten of categorieën klanten. Omdat het moeilijk kan zijn om onwettig gedrag van deze soort te onderscheiden van rechtmatig gedrag, dient u de Juridische Afdeling van Avient te raadplegen voordat u een van deze soorten beperkingen toepast. 4. Verzamel niet anderszins informatie (met name prijsinformatie) rechtstreeks van concurrenten. 4.

4 ISIN code - bond (1.6.1) Does your organization use this unique identifier? Board of Directors Committees as discussed in the Governance section of this Report 4. Switch off lights after finishing duty, including computers and AC.

We also generated 4% and 1% organic sales growth in EMEA and Asia, respectively. https://www.avient.com/investors https://edge.media-server.com/mmc/p/pyh3w2ip/ https://www.avient.com/investors https://register.vevent.com/register/BId7a8a09515a442e9b13c4d5558d927fe https://www.avient.com/investors/events-presentations 4 Non-GAAP Financial Measures The Company uses both GAAP (generally accepted accounting principles) and non-GAAP financial measures. 2) Tax adjustments include the net tax impact from non-recurring income tax items, adjustments to uncertain tax position reserves and the establishment, reversal or changes to valuation allowances. 10 Attachment 4 Avient Corporation Condensed Consolidated Balance Sheets (In millions) (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 489.4 $ 545.8 Accounts receivable, net 486.6 399.9 Inventories, net 365.9 347.0 Other current assets 117.2 114.9 Total current assets 1,459.1 1,407.6 Property, net 1,019.9 1,028.9 Goodwill 1,685.1 1,719.3 Intangible assets, net 1,515.7 1,590.8 Other non-current assets 228.0 221.9 Total assets $ 5,907.8 $ 5,968.5 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term and current portion of long-term debt $ 657.7 $ 9.5 Accounts payable 435.2 432.3 Accrued expenses and other current liabilities 405.3 331.8 Total current liabilities 1,498.2 773.6 Non-current liabilities: Long-term debt 1,420.8 2,070.5 Pension and other post-retirement benefits 63.3 67.2 Deferred income taxes 276.3 281.6 Other non-current liabilities 315.0 437.6 Total non-current liabilities 2,075.4 2,856.9 SHAREHOLDERS' EQUITY Avient shareholders’ equity 2,317.5 2,319.2 Noncontrolling interest 16.7 18.8 Total equity 2,334.2 2,338.0 Total liabilities and equity $ 5,907.8 $ 5,968.5 11 Attachment 5 Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions) Six Months Ended June 30, 2024 2023 Operating Activities Net income $ 83.5 $ 42.7 Adjustments to reconcile net income to net cash provided (used) by operating activities: Depreciation and amortization 88.4 96.2 Accelerated depreciation 0.8 1.9 Share-based compensation expense 9.0 6.5 Changes in assets and liabilities: Increase in accounts receivable (97.0) (66.6) (Increase) decrease in inventories (27.3) 14.0 Increase (decrease) in accounts payable 11.9 (26.2) Taxes paid on gain on sale of business — (103.0) Accrued expenses and other assets and liabilities, net (6.2) 9.8 Net cash provided (used) by operating activities 63.1 (24.7) Investing activities Capital expenditures (55.8) (45.9) Net proceeds from divestiture — 7.3 Proceeds from plant closures 3.4 — Other investing activities (2.1) — Net cash used by investing activities (54.5) (38.6) Financing activities Cash dividends paid (47.0) (45.0) Repayment of long-term debt (4.5) (1.0) Other financing activities (3.3) (2.3) Net cash used by financing activities (54.8) (48.3) Effect of exchange rate changes on cash (10.2) (0.8) Decrease in cash and cash equivalents (56.4) (112.4) Cash and cash equivalents at beginning of year 545.8 641.1 Cash and cash equivalents at end of period $ 489.4 $ 528.7 12 Attachment 6 Avient Corporation Business Segment Operations (Unaudited) (In millions) Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.